title: Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.
abstract: BACKGROUND
  The goal of this study was to determine the association of multiple antibiotic-resistant Pseudomonas aeruginosa (MARPA) acquisition with lung function decline in patients with cystic fibrosis (CF).
  
  
  METHODS
  Using data from Epidemiologic Study of Cystic Fibrosis (ESCF), we identified patients with spirometry data and MARPA, defined as PA (1) resistant to gentamicin and either tobramycin or amikacin, and (2) resistant to ≥1 antipseudomonal beta lactam. MARPA had to be detected in a respiratory culture after ≥2 years of PA-positive but MARPA-negative respiratory cultures. Multivariable piecewise linear regression was performed to model the annual rate of decline in forced expiratory volume in 1 second (FEV(1)) % predicted 2 calendar years before and after the index year of MARPA detection, adjusting for patient characteristics and CF therapies.
  
  
  RESULTS
  In total, 4349 patients with chronic PA and adequate PFT data were identified; 1111 subsequently developed MARPA, while 3238 patients were PA positive but MARPA negative. Compared with patients who did not acquire MARPA, MARPA-positive patients had lower FEV(1) and received more oral (p<0.013) and inhaled (p<0.001) antibiotic therapy. Mean FEV(1) decline did not change significantly after MARPA detection (-2.22% predicted/year before detection and -2.43 after, p=0.45). There was no relationship between persistent infection or FEV(1) quartile and FEV(1) decline.
  
  
  CONCLUSIONS
  Newly detected MARPA was not associated with a significant change in the rate of FEV(1) decline. These results suggest that MARPA is more likely to be a marker of more severe disease and more intensive therapy, and less likely to be contributing independently to more rapid lung function decline.
authors.affiliation: University of Rochester, Rochester, NY, USA. Clement_Ren@URMC.Rochester.edu
authors.forename: Clement L
authors.initials: CL
authors.lastname: Ren
authors.forename: Michael W
authors.initials: MW
authors.lastname: Konstan
authors.forename: Ashley
authors.initials: A
authors.lastname: Yegin
authors.forename: Lawrence
authors.initials: L
authors.lastname: Rasouliyan
authors.forename: Benjamin
authors.initials: B
authors.lastname: Trzaskoma
authors.forename: Wayne J
authors.initials: WJ
authors.lastname: Morgan
authors.forename: Warren
authors.initials: W
authors.lastname: Regelmann
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D003550:Cystic Fibrosis / Q000453:epidemiology / Q000382:microbiology* / Q000503:physiopathology; D024881:Drug Resistance, Bacterial; D018432:Drug Resistance, Multiple; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000453:epidemiology*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000453:epidemiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012129:Respiratory Function Tests; D013147:Spirometry; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents